UKINETS2020 Poster Presentations (1) (16 abstracts)
Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0
Irvin Modlin 1 , Mark Kidd 2 , Kjell Oberg 3 , Massimo Falconi 4 , Pier Luigi Filosso 5 , Andrea Frilling 6 , Anna Malczewska 7 , Ronald Salem 1 , Christos Toumpanakis 8 , Faidon-Marios Laskaratos 8 , Stefano Partelli 4 , Matteo Roffinella 5 , Claudia von Arx 8 , Beata Kos-Kudla 7 , Lisa Bodei 9 , Ignat Drozdov 2 & Alexandra Kitz 2
1Yale University, New Haven, Connecticut, USA; 2Wren Laboratories, Branford, Connecticut, USA; 3University Hospital, Uppsala, Sweden; 4San Rafaelle IRCCS, Milan, Italy; 5University of Torino, Turin, Italy; 6Imperial College, London, UK; 7Medical University of Silesia, Katowice, Poland; 8Royal Free Hospital, London, UK; 9Memorial Sloan Kettering Cancer Center, New York, USA
Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would detect residual disease (after R1/R2) and could be used to predict recurrence in R0.
Methods: Multicenter evaluation of surgically treated primary NETs (n=153). Blood sampling at D0 and POD30. Follow-up including CT/MRI. mRNA quantification by PCR and algorithmic analysis (NETest score: 0–100; normal<20). Statistics: Mann-Whitney U-test, Chi2, Kaplan-Meier survival, AUROC. Mean±S.E.M.
Results: NET-cohort (n=153): 57 pancreatic, 62 small bowel, 27 lung, 4 duodenal, 3 gastric. Surgery: R0 (n=102), R1and R2 (n=51). Follow-up: mean 14 months (range 3–68). Preop 153/153 NETest-positive (68±28). R1/R2 Cohort: Score decreased (73±26 to 52±27). At POD30, 100% were elevated (P<0.0001). R0 Cohort: POD30 levels decreased from 62±28 to 22±20 (P<0.0001). 30% (31/102) remained elevated: 28% lung, 29% pancreas, 27% small bowel and 1/3 gastric. Recurrence: By 12 months, 24/31 (74%) with POD30 NETest>20 had image-identifiable recurrence. NETest>20 predicted recurrence with 100% sensitivity and correlated highly (Chi2=17.1, P<0.0001) with residual disease. AUROC analysis identified AUC=0.96 (P<0.0001) for recurrence-prediction.
Conclusion: A liquid biopsy (NETest) genomic biomarker for neuroendocrine tumors is 100% accurate for tumor diagnosis. All resections decreased NETest levels. NETest>20 at POD30 predicted radiologically recurrent disease with 93% accuracy and 100% sensitivity. R0 resection appears to be ineffective in ˜30%. NET mRNA blood levels provide early objective genomic identification of residual disease and may facilitate management.
Volume 72
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more